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Abstract 
Review on PLCG1, with data on DNA/RNA, on the 
protein encoded and where the gene is implicated. 
Identity 
Other names: NCKAP3, PLC-II, PLC1, PLC148, 
PLCgamma1 
HGNC (Hugo): PLCG1 
Location: 20q12 
Local order: From the cytosol. 
DNA/RNA 
Description 
The PLCG1 gene spans 38.762 kb on the genomic 
DNA. The gene includes 32 exons. 
Transcription 
There are two transcript variants: 5205 bp (isoform 
a) and 5202 bp (isoform b). 
Protein 
Description 
The PLCG1 protein encodes two alternative  
isoforms: variant a (P19174-1)-1290 amino acids, 
148.53 Da; variant b (P19174-2)-1291 amino acids, 
148.66 Da. 
Expression 
PLCG1 is expressed ubiquitously, especially in the 
brain, thymus, intestine and lungs. Additionally, 
PLCG1 is overexpressed in numerous cancer types 
such as human colorectal cancer (Noh et al., 1994), 
breast carcinoma (Arteaga et al., 1991), prostate 
carcinoma (Peak et al., 2008), familial adenomatous 
polyposis (Park et al., 1994) and human skins under 
hypeproliferative conditions (Nanney et al., 1992). 
Localisation 
PLCG1 localizes predominantly in the plasmatic 
membrane, cytoplasm and nucleus. 
Function 
PLCG1 is a protein involved in multiple cellular 
processes. A potent inhibitor of PLCG1 (U-73122) 
has been reported to inhibit PLCG1-dependent 
processes in cells (Smith et al., 1990; Thompson et 
al., 1991; Thomas et al., 2003; Li et al., 2005).  
The inhibition of PLCG1 may be an important 
mechanism for an antiproliferative effect on the 
human cancer cells. 
Role in the production of the second messenger 
molecules: PLCG1 mediates the production of 
diacylglycerol (DAG) and inositol 1,4,5-
trisphosphate (IP3) from the hydrolysis of 
phosphatidynositol-4,5-bisphosphate (PIP2) 
(Williams et al., 1996). These second messengers 
are essential for T cell activation (Lin et al., 2001). 
 
 
Figure 1. Schematic diagram of PLCG1 location on chromosome 20. PLCG1 localizes to chromosome 20q12, which is 
represented graphically. PLCG1 gene spans 38.762 kb on the genomic DNA. 
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Figure 2. Schematic representation of the domains of PLCG1. The protein contains eight domains, four of which are unique 
to PLCG family. The PLCG 'specific array' of domains, comprising a "split" PH domain flanking two tandem SH2 domains and 
one SH3 domain, is inserted between the two halves (X and Y) of the TIM-barrel catalytic domain. Several other domains 
including two PH domains, one C2 domain and one EF hand motifs. The numering of the amino acid residues is for human 
PLCG1 (Suh et al., 2008; Bunney and Katan, 2011). 
 
 
Role in cellular proliferation: PLCG1 is associated 
with tumor development, and it is overexpressed in 
some tumors (Shin et al., 2007). This 
overexpression stimulates MMP-3 expression. 
PLCG1 is required for metastasis development 
(Sala et al., 2008). 
Role in angiogenesis: PLCG1 plays an important 
role in angiogenesis (Husain et al., 2010). PLCG1 
is activated by vascular endothelial growth factor 
receptor-2 (VEGFR-2) in endothelial cells (Singh et 
al., 2007) and in neoplastic Barrett's cells (Zhang et 
al., 2013). 
Role in the regulation of intracellular signaling: 
PLCG1 plays a role in mediating T-cell activities 
downstream of TCR activity.  
PLCG1 can be activated by receptor tyrosine 
kinases: EGFR (Nishibe et al., 1990; Wu et al., 
2009), PDGFR (Larose et al., 1993), FGFR (Peters 
et al., 1992), NGFR (Middlemas et al., 1994) and 
HGFR (Davies et al., 2008). PLCG1 is a molecule 
associate with lipid rafts, it translocates from the 
cytosol to lipid rafts during TCR signaling (Verí et 
al., 2001). 
Role in the mobilization of Ca2+: this process is to 
activate phosphatase calcineurin, which in turn 
dephosphorylates and activates NFAT (Rao et al., 
1997).  
Truncation of the N terminus of Vav1 is 
accompanied by a decrease in PLCG1 
phosphorylation and this inhibits calcium 
mobilization (Knyazhitsky et al., 2012). 
Role in cytoskeleton: PLCG1 plays a role in actin 
reorganization (Pei et al., 1996; Wells, 2000; Wang 
et al., 2007; Li et al., 2009). 
Role in adhesion and migration: PLCG1 mediates 
cell adhesion and migration through an undefined 
mechanism (Wang et al., 2007; Crooke et al., 
2009). PLCG1 plays a role in integrin-mediated cell 
motility processes (Jones et al., 2005). 
Role in apoptosis: PLCG1 is proteolytically cleaved 
by group II caspases especially by caspase-3 and 
caspase-7 during apoptosis. This results in the loss 
of receptor-mediated tyrosine phosphorylation (Bae 
et al., 2000). PLCG1 plays a protective role in 
H2O2-induced PC12 cells death (Yuan et al., 2009). 
The Fas-mediated apoptosis requires endoplasmic 
reticulum-mediated calcium release in a mechanism 
dependent on PLCG1 activation (Wozniak et al., 
2006). 
Role in transformation: PLCG1 interacts with 
Middle tumor antigen (MT).  
The tyrosine phosphorylation level of PLCG1 is 
elevated in cells expressing wild type MT but not in 
cells expressing Tyr322→Phe MT (Su et al., 1995). 
Role in autoimmune symptoms: PLCG1 deficiency 
impairs the development and function regulatory 
cells (FoxP3+), causing inflammatory/autoimmune 
symptoms (Fu et al., 2010). 
Homology 
The protein contains eight domains, four of which 
are unique to PLCG family (Suh et al., 2008).  
The PLCG 'specific array' of domains, comprising a 
"split" PH domain flanking two tandem SH2 
domains and one SH3 domain, is inserted between 
the two halves (X and Y) of the TIM-barrel 
catalytic domain (Bunney and Katan, 2011). 
Several other domains including two PH domains, 
one C2 domain and one EF hand motifs (Suh et al., 
2008). 
Mutations 
Somatic 
99 mutations have been described in the PLCG1 
gene, according to the Catalogue of Somatic 
Mutations in Cancer (COSMIC) database.  
De novo mutation has been described in patients 
with Cutaneous T-cell lymphoma (CTCL): S345F 
(10/53 analyzed CTCL samples, 19%) (Vaqué et 
al., 2014). 
Implicated in 
Breast cancer 
Oncogenesis 
Overexpression of PLCG1 is a marker of 
development of metastases in breast cancer 
(Lattanzio et al., 2013).  
Loss of PLCG1 in part mimicked the effect of miR-
200b/miR-c/miR-429 overexpression in viability, 
apoptosis and EGF-driven cell invasion of breast 
cancer cells (Uhlmann et al., 2010). 
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Colorectal cancer 
Oncogenesis 
PLCG1 has a potencial role in colon cancer 
(Nomoto et al., 1995; Li et al., 2005; Reid et al., 
2009). The activity of PLCG1 is reduced in STAT3 
Y705F mutant colorectal cancer cells (Zhang et al., 
2011), it shows that there is crosstalk between 
STAT3 and PLCG1 signaling pathways. 
Prostate carcinoma 
Oncogenesis 
PLCG1 has a role in the regulation of PC3LN3 
(human prostate carcinoma cells) cell adhesion that 
appears to be independent of its effects on tumour 
cell chemotactic migration and spreading in 
response to extracellular matrix (Peak et al., 2008). 
Gastric cancer 
Oncogenesis 
PLCG1 plays a role in RhoGDI2-mediated cisplatin 
resistance and cell invasion in gastric cancer (Cho 
et al., 2011). 
Squamous cell carcinoma (SCC) 
Oncogenesis 
PLCG1 is a downstream target of EGFR signaling. 
PLCG1 is required for EGFR-induced SCC cell 
mitogenesis (Xie et al., 2010). 
Oral potentially malignant lesions 
(OPLs) 
Oncogenesis 
PLCG1 is highly expressed in oral cancer lesions 
compared with normal oral mucosa (Ma et al., 
2013). 
Esophageal adenocarcinoma 
Oncogenesis 
PLCG1-PKC-ERK pathway promotes proliferation 
and it is activated by VEGFR-2 in neoplastic 
Barrett's cells (Zhang et al., 2013). 
Pheochromocytoma (PC) 
Oncogenesis 
PLCG1 plays a role in apoptosis of PC12 cells 
induced by H2O2 (Yuan et al., 2009). 
Glioblastoma 
Oncogenesis 
PLCG1 is associated with lifetime and overall 
survival in glioblastoma and it can be a novel 
biomarker of this desease (Serão et al., 2011). 
Cutaneous T-cell lymphoma (CTCL) 
Oncogenesis 
The mutation in the catalytic domain of PLCG1 
(S345F) is detection in patients with CTCL. PLCG1 
mutants induced enhanced PLCG1 downstream 
signaling towards NFAT activation (Vaqué et al., 
2014). 
Brain disorders 
Note 
Jang et al., 2013. 
Oncogenesis 
PLCG1 is highly expressed in brain. Abnormal 
expression and activation of PLCG1 appears in 
epilepsy (He et al., 2010), bipolar disorder (Løvlie 
et al., 2001), depression (Dwivedi et al., 2005), 
Huntington's disease (Giralt et al., 2009) and 
Alzheimer's disease (Shimohama et al., 1995). 
Myocardial dysfunction in sepsis 
Oncogenesis 
PLCG1 signaling induces cardiac TNF-alpha 
expression and myocardial dysfunction during 
Lipopolysaccharide (LPS) stimulation. Inhibition of 
PLCG1 decreased cardiac TNF-alpha expression 
and LPS-induced myocardial dysfunction was also 
attenuated (Peng et al., 2008). 
To be noted 
Note 
miR that target PLCG1: PLCG1 is target of 
different microRNAs, according to the 
bioinformatic algorithms microRNA 
(microRNA.org). 
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